pch-2/bmk-1 Platform

About Eternity Biotech

Eternity Biotech is a private, pre-revenue biotech company pioneering a novel approach to life extension and anti-aging based on genetic targets pch-2 and bmk-1. Founded in 2016, the company has demonstrated proof-of-concept in C. elegans, showing a 25% lifespan extension, and has begun translating this work into human cell models. Led by a founder with a venture capital background and a CSO with drug development experience, the company is currently raising capital via a WeFund campaign to advance its research toward therapeutic development.

Therapeutic Areas